These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

326 related items for PubMed ID: 17069059

  • 1. [The use of beta-interferon-1b in children and adolescents with multiple sclerosis].
    Bykova OV, Kuzenkova LM, Maslova OI.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2006; 106(9):29-33. PubMed ID: 17069059
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Long-term experience with interferon beta-1b (Betaferon)in multiple sclerosis.
    Arnason BG.
    J Neurol; 2005 Sep; 252 Suppl 3():iii28-iii33. PubMed ID: 16170497
    [Abstract] [Full Text] [Related]

  • 4. [Multiple sclerosis in children and adolescents: history and current experience of immunomodulating treatment].
    Bykova OV, Maslova OI, Guseva MR, Boĭko SIu, Totolian NA, Matveeva TA, Boĭko AN.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2004 Sep; 104(4):4-10. PubMed ID: 15270293
    [Abstract] [Full Text] [Related]

  • 5. [Effective treatment of multiple sclerosis with rebif-22 mcg in children and adolescences: results of a long-term study].
    Bykova OV, Studenikin VM, Kuzenkova LM, Maslova OI, Boĭko AN.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2006 Sep; Spec No 3():116-21. PubMed ID: 17172246
    [Abstract] [Full Text] [Related]

  • 6. [Certain problems of therapy with beta-interferon preparations].
    Gusev EI, Demina TL, Boĭko AN, Khachanova NV.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2003 Sep; (Spec No 2):98-102. PubMed ID: 12938643
    [Abstract] [Full Text] [Related]

  • 7. [Clinical efficacy and safety of long-term immunomodulating therapy with interferon beta].
    Demina TL, Khachanova NV, Davydovskaia MV, Popova NF, Gusev EI.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008 Sep; 108(4):24-6. PubMed ID: 18567192
    [No Abstract] [Full Text] [Related]

  • 8. Autoantibodies in multiple sclerosis patients before and during IFN-beta 1b treatment: are they correlated with the occurrence of autoimmune diseases?
    Verdun E, Isoardo G, Oggero A, Ferrero B, Ghezzi A, Montanari E, Zaffaroni M, Durelli L, Betaferon Safety Trial (BEST) Study Group.
    J Interferon Cytokine Res; 2002 Feb; 22(2):245-55. PubMed ID: 11911808
    [Abstract] [Full Text] [Related]

  • 9. Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b.
    Frese A, Bethke F, Lüdemann P, Stögbauer F.
    Neurology; 1999 Nov 10; 53(8):1892-3. PubMed ID: 10563657
    [No Abstract] [Full Text] [Related]

  • 10. Multiple sclerosis and interferon beta-1b, past, present and future.
    Horowski R.
    Clin Neurol Neurosurg; 2002 Jul 10; 104(3):259-64. PubMed ID: 12127665
    [No Abstract] [Full Text] [Related]

  • 11. Multiple sclerosis, interferon beta-1b and depression A prospective investigation.
    Feinstein A, O'Connor P, Feinstein K.
    J Neurol; 2002 Jul 10; 249(7):815-20. PubMed ID: 12140662
    [Abstract] [Full Text] [Related]

  • 12. [Cognitive disturbances and attempts of their correction in multiple sclerosis].
    Shmidt TE.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2005 Jul 10; 105(9):54-6. PubMed ID: 16252387
    [No Abstract] [Full Text] [Related]

  • 13. The role of interferons in the treatment of multiple sclerosis.
    Kelley CL.
    J Neurosci Nurs; 1996 Apr 10; 28(2):114-20. PubMed ID: 8718760
    [Abstract] [Full Text] [Related]

  • 14. [Experience in the treatment of multiple sclerosis with interferon beta in Galicia].
    Romero-López J, Seijo-Martínez M, Del Campo V, Amigo-Jorrín MC, Arias M, Cortés-Laíño JA, Dapena-Bolaño D, López-González FJ, Lorenzo-González JR, Marín-Sánchez M, Muñoz-García D, Ozaita-Arteche G, Prieto JM.
    Rev Neurol; 1996 Apr 10; 37(11):1001-4. PubMed ID: 14669137
    [Abstract] [Full Text] [Related]

  • 15. Interferons in MS Treatment: report from the Canadian MS Forum symposium, 26-29 August 2004, Québec, Canada.
    Duquette P.
    Int MS J; 2005 Apr 10; 12(1):33-4. PubMed ID: 15955277
    [Abstract] [Full Text] [Related]

  • 16. [Report from the Satellite Symposium: Leading the way: outstanding efficacy of interferon beta-1b right from the start. Berlin, Germany, 06.24.2002].
    Cendrowski W.
    Neurol Neurochir Pol; 2002 Apr 10; 36(6):1260-3. PubMed ID: 12715704
    [No Abstract] [Full Text] [Related]

  • 17. [Betaferon in the treatment of multiple sclerosis: efficacy standards].
    Totolian NA.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2005 Apr 10; 105(7):63-6. PubMed ID: 16117152
    [No Abstract] [Full Text] [Related]

  • 18. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis.
    Montalban X, Sastre-Garriga J, Tintoré M, Brieva L, Aymerich FX, Río J, Porcel J, Borràs C, Nos C, Rovira A.
    Mult Scler; 2009 Oct 10; 15(10):1195-205. PubMed ID: 19797261
    [Abstract] [Full Text] [Related]

  • 19. Contemporary immunomodulatory therapy for multiple sclerosis.
    Rudick RA.
    J Neuroophthalmol; 2001 Dec 10; 21(4):284-91. PubMed ID: 11756861
    [Abstract] [Full Text] [Related]

  • 20. [Beta interferon in multiple sclerosis: pharmacological differences].
    Allain H, Bentué-Ferrer D, Schück S, Ruffault A.
    Rev Neurol (Paris); 1999 Dec 10; 155 Suppl 2():S24-30. PubMed ID: 10367322
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.